|
 Role of PPARs in the Treatment of Insulin Resistance & Cardiovascular Disease
Faculty: Lawrence Blonde, MD, FACP, FACE | James R Gavin III, MD, PhD
CME Credit hour: 1.0
This CME initiative provides primary care providers, endocrinologists and cardiologists, who are the forefront in preventing and treating diabetes and CVD, with up-to-date information on the role of PPARs in the treatment of insulin-resistant diabetes and CVD. Topics of discussion include the interrelationship and impact of diabetes, metabolic syndrome, and CVD; current treatment strategies and unmet needs; safety and efficacy data on PPAR activators; and the potential clinical application of dual alpha-gamma PPAR activators.
 Cardiovascular and Renal Protection In Patients with Diabetes and Metabolic Syndrome (Accreditation Expired)
Faculty: George L. Bakris, MD, F.A.S.N.
CME Credit hour: 1.0
Micro- and macrovascular complications affecting the heart and kidneys are a major cause of morbidity and mortality in patients with diabetes and the metabolic syndrome. Aggressive blood pressure management, in addition to glycemic and lipid management, can provide significant cardiovascular and renal protection in this high-risk patient population. Controlling blood pressure has been shown to reduce cardiovascular disease and microvascular disease. However, many patients with hypertension receive no or suboptimal treatment, and most of those patients do not reach the recommended blood pressure goals.
This program addresses the challenges faced by clinicians who treat hypertension and provides evidence-based strategies for optimizing blood pressure control to prevent cardiovascular and renal complications in patients with diabetes and the metabolic syndrome.
|
